Skip to main content
SpringerLink
Log in

Efficacy and Tolerability of Meloxicam versus Piroxicam in Patients with Osteoarthritis of the Hip or Knee

A Six-Month Double-Blind Study

  • Clinical Use
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Summary

This study compared the efficacy and tolerability of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), with piroxicam in a randomised, double-blind, parallel-group trial. 455 patients with proven osteoarthritis of the knee or hip were randomised in a ratio of 2:1 to receive meloxicam 15mg once daily (n = 306) or piroxicam 20mg once daily (n = 149) for a 6-month period. In the evaluation of efficacy end-points (overall pain, pain on movement, joint stiffness, global efficacy and quality of life), both drug treatments were shown to be effective and comparable. The incidence and type of adverse events were similar in both groups. The most frequently reported adverse events were gastrointestinal disorders, reported in 24.2% of meloxicam-treated patients and 30.2% of piroxicam-treated patients. Both drugs were well tolerated. In conclusion, meloxicam is an effective and well tolerated drug for the symptomatic treatment of osteoarthritis and is comparable in efficacy to piroxicam.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Larkai E, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989; 11(2): 158–62

    Article  PubMed  CAS  Google Scholar 

  2. Coles LS, Fries JF, Kraines RG, et al. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983; 74: 820–8

    Article  PubMed  CAS  Google Scholar 

  3. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213–22

    Article  PubMed  CAS  Google Scholar 

  4. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs - differences and similarities. N Engl J Med 1991; 324(24): 1716–25

    Article  PubMed  CAS  Google Scholar 

  5. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647–55

    PubMed  CAS  Google Scholar 

  6. Kirchner JT. Nonsteroidal anti-inflammatory drug use in the elderly. Issues of compliance and safety. JAMA 1994; 94(4): 300–4

    CAS  Google Scholar 

  7. Lund B, Distel M, Bluhmki E. A double-blind placebo controlled study of the different doses of meloxicam in patients with osteoarthritis (OA) of the knee [abstract 117]. 25th Scandinavian Congress of Rheumatology, Lillehammer, Norway, 1-4 June 1994. Scand J Rheumatol 1994; Suppl. 98

  8. Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423–33

    Article  PubMed  CAS  Google Scholar 

  9. Engelhardt G, Bogel R, Schnitzler Chr, et al. Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem Pharmacol 1996; 51: 21–8

    Article  PubMed  CAS  Google Scholar 

  10. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, editors. Improved non-steroidal anti-inflammatory drugs. London, UK: Kluwer Academic Publishers, 1996: 103–19

    Chapter  Google Scholar 

  11. Churchill L, Graham AG, Shih C-K, et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 1996; 4: 125–35

    Article  CAS  Google Scholar 

  12. Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35(1 Suppl.): 13–6

    Article  PubMed  Google Scholar 

  13. Lauffen H, Leitpolt M. The effect of activated charcoal on the bioavailability of piroxicam in man. Int J Clin Pharmacol Ther Toxicol 1986; 24(1): 48–52

    Google Scholar 

  14. Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994; 26(1): 16–43

    Article  PubMed  CAS  Google Scholar 

  15. Martini C, Hunt S. The Nottingham Health Profile. In: S. Mc-Dowell, C. Newell, editors. Measuring Health: Oxford University Press, 1981

  16. Karch FE, Lasagna L. Adverse drug reactions. JAMA 1975; 234: 1236–41

    Article  PubMed  CAS  Google Scholar 

  17. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl. 1989; 163: 3–8

    Article  PubMed  CAS  Google Scholar 

  18. Lindèn B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35Suppl. 1: 35–8

    Article  PubMed  Google Scholar 

  19. Brogden RN, Heel RC, Speight TM, et al. Piroxicam: a reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28: 292–323

    Article  PubMed  CAS  Google Scholar 

  20. Moser U, Waldburger H, Schwarz HA, et al. A double-blind randomised multicentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. Scand J Rheumatol 1989; Suppl. 80: 71–80

    Article  Google Scholar 

  21. Paulsen GA, Baigun S, de Figueiredo JG, et al. Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. Curr Med Res Opin 1991; 12(6): 401–12

    Article  Google Scholar 

  22. Lewis T, Lain D, Baumgartner SW. Comparison of diflunisal and piroxicam in the management of patients with osteoarthritis. Clin Ther 1986; 9Suppl. C: 15–26

    PubMed  Google Scholar 

  23. Huskisson EC, Greenwood A. Naproxen and piroxicam. A comparative trial in rheumatoid arthritis. Eur J Rheumatol Inflamm 1983; 6: 242–6

    PubMed  CAS  Google Scholar 

  24. Husby G, Holme I, Rugstad HE, et al. A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. Clin Rheumatol 1986; 5(1): 84–91

    Article  PubMed  CAS  Google Scholar 

  25. Al Nahdi M. Efficacy and tolerability of long-term tenoxicam versus piroxicam in patients with rheumatoid arthritis or osteoarthritis. Curr Ther Res Clin Exp 1992; 52(4): 639–45

    Article  Google Scholar 

  26. Waterworth RF, Waterworth SM, Taylor KM. A comparison of tenoxicam and piroxicam in a long-term clinical study in patients with osteoarthritis of hip or knee joints. Eur J Rheumatol Inflamm 1985; 8(1): 21–7

    PubMed  CAS  Google Scholar 

  27. Lund B, Andersen RB, Fossgreen J, et al. A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12-24 month interval. Eur J Rheumatol Inflamm 1987; 9(1-2): 58–67

    PubMed  CAS  Google Scholar 

  28. Hunt SM, McKenna SP, Williams J. Reliability of a population survey tool for measuring perceived health problems: a study of patients with osteoarthrosis. J Epidemiol Community Health 1981; 35: 297–300

    Article  PubMed  CAS  Google Scholar 

  29. Hunt SM, McEwen J, McKenna SP, et al. Subjective health of patients with peripheral vascular disease. Practitioner 1982; 226: 133–6

    PubMed  CAS  Google Scholar 

  30. Engelhardt G, Bögel R, Schnitzler CHR, et al. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51: 29–38

    Article  PubMed  CAS  Google Scholar 

  31. Vane J. Towards a better aspirin. Nature 1994; 367: 215–6

    Article  PubMed  CAS  Google Scholar 

  32. Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology 1996; 4: 71–81

    Article  CAS  Google Scholar 

  33. Kirchner JT. Nonsteroidal anti-inflammatory drug use in the elderly: issues of compliance and safety. J Am Ostoepath Assoc 1994; 94(4): 300–4

    CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank the following investigators who participated in this trial: Dr J.K. Agarwala, Manchester; Dr P. Barnard, W. Kirby; Dr B. Barber, Leicester; Dr I. Bhatia, Ipswich; Dr M. Bhowmik, Derbyshire; Dr P. Brahma, Knottingley; Dr S. Chouksey, Manchester; Dr R.B. Deering, Burgess Hill; Dr P. Devichand, Llanelli; Dr H. Donnachie, Glasgow; Dr T. Dudeney, Henley-on-Thames; Dr G. Fairhurst, St Helens; Dr R. Gerlis, Harlow; Dr J.D. Griffiths, Barnsley; Dr M.J. Hossain, Gwent; Dr J.M. Howard, Liverpool; Dr I.W. Hughes, Waterloo; Dr B.K. Jaiswal, Dagenham; Dr D.P. Jaiswal, Dagenham; Dr G.N. Jamieson, Radcliffe on Trent; Dr N. Joshi, Tyne & Wear; Dr M. Kannan, Wigmore; Dr M. Kansagra, Milton Keynes; Dr N.N. Kassam, Salford; Dr M. Khong, Leicester; Dr D. Laws, Tyne & Wear; Dr F. Lustman, Tyne & Wear; Dr S.K. Mahanty, Eastmoor; Dr A. Miller, Eastbourne; Dr M. Morris, Alyth; Dr R. Jones, Sheffield; Dr I. Reid, Glasgow; Dr H. Richards, Brighton; Dr L. Ritchie, Grampian; Dr M. Saika, Knottingley; Dr S. Saikia, Birmingham; Dr A. Scatchard, Harrogate; Dr S. Shah, Blackwood; Dr N.K. Sharma, Southport; Dr R. Thakor, Leicester; Dr J. Vernon, Dundee; Dr A. Virji, London; Dr D. Wheatcroft, Letchworth.

This work was funded by Dr Karl Thomae GmbH, Biberach, Germany.

Author information

Authors and Affiliations

  1. Great Western Medical, 1980 Great Western Road, Glasgow, G13 2SW, Scotland

    J. Hosie

  2. Departamento Medico, Boehringer Ingelheim SA, Buenos Aires, Argentina

    M. Distel

  3. Boehringer Ingelheim GmbH, Biberach, Germany

    E. Bluhmki

Authors
  1. J. Hosie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Distel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Bluhmki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hosie, J., Distel, M. & Bluhmki, E. Efficacy and Tolerability of Meloxicam versus Piroxicam in Patients with Osteoarthritis of the Hip or Knee. Clinical Drug Investigation 13, 175–184 (1997). https://doi.org/10.2165/00044011-199713040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199713040-00001

Keywords

Search

Navigation